Insider · CIK 0000919484
Mark E Strome
Files at ZIVO (Zivo Bioscience, Inc.), BEATW (HeartBeam, Inc.). First filing Dec 31, 2024, latest Apr 24, 2026.
In brief
Mark E Strome files SEC Form 4 as 10% owner and director at ZIVO (Zivo Bioscience, Inc.), and also at BEATW (HeartBeam, Inc.). Since Dec 31, 2024, Mark E Strome has reported 5 open-market buys worth $2.8M and 1 open-market sell worth $895k, the latest filed on Apr 24, 2026.
After Mark E Strome's past buys, the stock trailed the S&P 500 by a median 72.5% over six months (n = 3), and 0% of those buys were ahead of the index at six months. InsiderTell labels that a negative record.
The newest scored trade: bought $200k of ZIVO on Apr 17, 2026, filed Apr 24, 2026, scored 43 (moderate). In the last 12 months: 4 buys worth $1.2M and 1 sell worth $895k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ZIVO: Zivo Bioscience, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | ZIVObuy Zivo Bioscience, Inc. | $200k 100,000 shares | +21% | 0% from low-89% from high | |
| 50Moderate | HeartBeam, Inc. | $600k 750,000 shares | +26% | - | |
| 35Weak | Zivo Bioscience, Inc. | $195k 20,000 shares | +4% | +42% from low-54% from high | |
| 44Moderate | HeartBeam, Inc. | $895k 250,000 shares | -8% | - | |
| 43Moderate | Zivo Bioscience, Inc. | $250k 20,259 shares | +5% | +32% from low-40% from high | |
| 38Weak | ZIVObuy Zivo Bioscience, Inc. | $1.5M 75,000 shares | +23% | - |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 17, 2026 | ZIVO Zivo Bioscience, Inc. | POpen-market purchase Common Stockindirect: By entity | +100,000 | $2.00 | $200k | 572,942 | Apr 24, 2026 |
| Apr 16, 2026 | BEATW HeartBeam, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +750,000 | $0.80 | $600k | 3,650,000 | Apr 16, 2026 |
| Feb 9, 2026 | BEATW HeartBeam, Inc. | AGrant or award Common Stock (right to buy)derivative | +41,380 | $0.00 | $0 | 41,380 | Mar 23, 2026 |
| Feb 12, 2026 | ZIVO Zivo Bioscience, Inc. | POpen-market purchase Common Stockindirect: By entity | +20,000 | $9.77 | $195k | 472,942 | Feb 17, 2026 |
| Feb 12, 2026 | ZIVO Zivo Bioscience, Inc. | POpen-market purchase Common Stock Purchase Warrantderivativeindirect: By entity | +2,000 | $0.00 | $0 | 45,071 | Feb 17, 2026 |
| Dec 17, 2025 | BEATW HeartBeam, Inc. | SOpen-market sale Common Stockindirect: See Footnote | -250,000 | $3.58 | $895k | 2,900,000 | Dec 22, 2025 |
| Oct 13, 2025 | ZIVO Zivo Bioscience, Inc. | POpen-market purchase Common Stockindirect: By entity | +20,259 | $12.34 | $250k | 452,942 | Oct 20, 2025 |
| Oct 13, 2025 | ZIVO Zivo Bioscience, Inc. | POpen-market purchase Common Stock Purchase Warrantderivativeindirect: By entity | +2,025 | $0.00 | $0 | 43,071 | Oct 20, 2025 |
| Dec 26, 2024 | ZIVO Zivo Bioscience, Inc. | POpen-market purchase Common Stockindirect: By entity | +75,000 | $20.19 | $1.5M | 398,683 | Dec 31, 2024 |
| Dec 26, 2024 | ZIVO Zivo Bioscience, Inc. | POpen-market purchase Common Stock Purchase Warrantderivativeindirect: By entity | +7,500 | $0.00 | $0 | 44,171 | Dec 31, 2024 |
Questions about Mark E Strome
Answered from the filings on this page, as of the latest one.
Is Mark E Strome buying or selling?
In the last 12 months Mark E Strome reported 4 open-market buys worth $1.2M and 1 open-market sell worth $895k on SEC Form 4; the latest was bought $200k of ZIVO on Apr 17, 2026. Grants, option exercises and tax withholding are not counted.
How did Mark E Strome's past buys perform?
Measured from the first close after each filing, the stock trailed the S&P 500 by a median 72.5% over six months across 3 past buys, with 0% ahead of the index. Past results describe what happened; they do not predict the next trade.
Where does Mark E Strome file Form 4?
Mark E Strome has filed Form 4 at ZIVO (Zivo Bioscience, Inc.); BEATW (HeartBeam, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.